Cardiology/Vascular Diseases

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Premier ProvideGx Program Partners with Pfizer

Lead Product(s): Ibutilide

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Premier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 19, 2020

Details:

Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.

Secarna Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

Lead Product(s): Antisense oligonucleotide therapies

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Lipigon

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 23, 2020

Details:

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

Milestone Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial

Lead Product(s): Etripamil

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

Details:

Etripamil (70mg) did not achieve its primary endpoint of time to conversion of SVT to sinus rhythm (SR) compared to placebo over the five hour period following study drug administration.

Esperion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™

Lead Product(s): Bempedoic Acid,Ezetimibe

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

Details:

The program evaluated the safety, tolerability and LDL-C lowering efficacy of NEXLETOL and NEXLIZET in patients with hypercholesterolemia.

Cytokinetics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Cytokinetics To Announce Baseline Characteristics From Galactic-Hf During ACC.20/WCC

Lead Product(s): Omecamtiv Mecarbil

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

Cytokinetics is conducting baseline characteristics from the cardiovascular outcomes trial of omecamtiv mecarbil, GALACTIC-HF.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Novartis announces NEJM publication of three pivotal trials

Lead Product(s): Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD).

Tenax Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Tenax Therapeutics Announces $2.75 Million Registered Direct Offering

Lead Product(s): Levosimendan

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: H.C. Wainwright & Co

Deal Size: $2.8 million Upfront Cash: Undisclosed

Deal Type: Public Offering March 12, 2020

Details:

Tenax currently intends to use the net proceeds from the offering to further its clinical trials of levosimendan, for research and development and general corporate purposes.

Correvio Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Correvio Partners with Hong Kong Teson Pharma Limited

Lead Product(s): Tirofiban Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hong Kong Teson Pharma

Deal Size: $3.5 million Upfront Cash: $3.0 million

Deal Type: Agreement March 10, 2020

Details:

The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.

Heartseed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

Lead Product(s): Allogeneic iPSC-derived cardiomyocytes

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Itochu Chemical Frontier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 10, 2020

Details:

Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.

UCB Pharma S.A.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products

Lead Product(s): Alprostadil

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Advanz Pharma

Deal Size: $98.0 million Upfront Cash: $84.0 million

Deal Type: Agreement March 06, 2020

Details:

The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

Find

Find Clinical Drug Pipelines for Cardiology/Vascular Diseases

A collaboration with SCORR Marketing

Product Type

Development Status

Pfizer Inc

Premier ProvideGx Program Partners with Pfizer

Secarna Pharma

Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

Milestone Pharmaceuticals

Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial

Esperion Therapeutics

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™

Cytokinetics

Cytokinetics To Announce Baseline Characteristics From Galactic-Hf During ACC.20/WCC

Novartis Pharmaceuticals Corporation

Novartis announces NEJM publication of three pivotal trials

Tenax Therapeutics

Tenax Therapeutics Announces $2.75 Million Registered Direct Offering

Correvio Pharma

Correvio Partners with Hong Kong Teson Pharma Limited

Heartseed

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

UCB Pharma S.A.

Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products